Publication
Prophylactic Use of Liposomal Amphotericin B in Preventing Fungal Infections Early After Liver Transplantation: a Retrospective, Single-Center Study
| dc.contributor.author | Antunes, AM | |
| dc.contributor.author | Teixeira, C | |
| dc.contributor.author | Corvo, ML | |
| dc.contributor.author | Perdigoto, R | |
| dc.contributor.author | Barroso, E | |
| dc.contributor.author | Marcelino, P | |
| dc.date.accessioned | 2015-05-19T12:14:35Z | |
| dc.date.available | 2015-05-19T12:14:35Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | In this study the authors evaluated the efficacy of prophylaxis with liposomal amphotericin B (L-AmB) in the incidence of fungal infections (FI) during the first 3 months after liver transplant (LT). The study was retrospective and accessed a 4-year period from 2008 to 2011. All patients who died in the first 48 hours after LT were excluded. Patients were divided by the risk groups for FI: Group 1, high-risk (at least 1 of the following conditions: urgent LT; serum creatinine >2 mg/dL; early acute kidney injury [AKI] after LT; retransplantation; surgical exploration early post-LT; transfused cellular blood components [>40 U]); and Group 2, low-risk patients. Group 1 patients were further separated into those who received antifungal prophylaxis with L-AmB and those who did not. Prophylaxis with L-AmB consisted of intravenous administration of L-AmB, 100 mg daily for 14 days. Four hundred ninety-two patients underwent LT; 31 died in the first 48 hours after LT. From the remaining 461 patients, 104 presented with high-risk factors for FI (Group 1); of these, 66 patients received antifungal prophylaxis and 38 did not. In this group 8 FI were observed, 5 in patients without antifungal prophylaxis (P = .011). Three more FI were identified in Group 2. By logistic regression analysis, the categorical variable high-risk group was independently related to the occurrence of invasive FI (P = .006). We conclude that prophylaxis with L-AmB after LT was effective in reducing the incidence of FI. No influence on mortality was detected. | por |
| dc.identifier.citation | Transplant Proc. 2014 Dec;46(10):3554-9 | por |
| dc.identifier.uri | http://hdl.handle.net/10400.17/2170 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Elsevier | por |
| dc.subject | HCC CHBPT | por |
| dc.subject | Retrospective Studies | por |
| dc.subject | Amphotericin B/administration & dosage | por |
| dc.subject | Antifungal Agents/administration & dosage | |
| dc.subject | Dose-Response Relationship, Drug | |
| dc.subject | Infusions, Intravenous | |
| dc.subject | Incidence | |
| dc.subject | Liver Transplantation | |
| dc.subject | Mycoses/epidemiology | |
| dc.subject | Mycoses/prevention & control | |
| dc.subject | Reoperation | |
| dc.title | Prophylactic Use of Liposomal Amphotericin B in Preventing Fungal Infections Early After Liver Transplantation: a Retrospective, Single-Center Study | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 3559 | por |
| oaire.citation.startPage | 3554 | por |
| oaire.citation.title | Transplantation Proceedings | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |